Summit says path forward for failed C. difficile drug is likely through partnerships - FierceBiotech
Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. | Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. It hopes to present more data in May. The blueprint from the company comes after its shares have plummeted 50% in the last six months.